Fig. 1 · Structure

Documents & Downloads

GW9508

Cat. No. A11965 CAS 885101-89-3

GPR40 Inhibitor

GW 9508 is a cell-permeable aminophenylpropanoate that acts as a potent and selective agonist for the G-protein coupled receptor (GPCR) GRP40/FFA1 receptor (EC50 ?50 nM) with reduced activity towards family members GRP120 (EC50 ?3.5 μM), GRP41/GRP43 (EC50 >50 μM), as well as a panel of eight other free fatty acid (FFA) and prostaglandin receptors.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
GPR40 pEC50 7.32
GPR120 pEC50 5.46

Cellular Effect

Cell Line Activity Value Description Reference
CHO EC50 13 nM Agonist activity at human GPR40 expressed in CHO cells by calcium flux assay [PMID: 24835985]
CHO EC50 99 nM Agonist activity at rat GPR40 expressed in CHO cells by calcium flux assay [PMID: 24835985]

In Vitro Studies

In cultured primary microglia from neonatal rat spinal cords, GW9508 increased POMC expression in a concentration-dependent manner, with an EC50 value of 13.4 μM. In senescent iTECs, GW9508 at 4.8 μM decreased the proportion of SA‐β‐gal positive cells from approximately 85% in the DOX‐treated group to about 20%. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

POMC expression in cultured primary microglia

Cell-based study · cultured primary microglia; spinal cords of 1-day-old neonatal rats [1]

Cultured primary microglia from neonatal rat spinal cords were incubated with GW9508 for 2 h. Treatment increased POMC expression in a concentration-dependent manner, with an EC50 value of 13.4 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mRNA expression of IL-10, POMC, and PDYN; quantitative real-time PCRPOMC expression EC50 value of 13.4 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
2 h
Method
GW9508 incubation
Vehicle
normal saline
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: GW9508

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Drugs and reagents (S5); Results > GW9508 stimulated IL-10 and β-endorphin expression in cultured primary microglia and astrocytes (S157, S159, S160, S163, S164)

mRNA expression of IL-10, POMC, and PDYN; quantitative real-time PCR: mRNA expression of IL-10, POMC, and PDYN; quantitative real-time PCR; comparator: control group — Results > GW9508 stimulated IL-10 and β-endorphin expression in cultured primary microglia and astrocytes (S159, S164)

SA‐β‐gal positivity in senescent thymic epithelial cells

Cell-based study · senescent iTECs; n = 3 [2]

Senescent iTECs were treated with GW9508 at 4.8 μM. The proportion of SA‐β‐gal positive cells decreased from approximately 85% in the DOX‐treated group to about 20% with GW9508 treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
quantification of SA‐β‐gal positive cellsproportion of SA‐β‐gal positive cells from approximately 85% in the DOX‐treated group to about 20%[2]

Literature-Reported Treatment Conditions

Treatment concentration
4.8 μM
Exposure duration
36 h; GW9508 treatment for 72 h
Co-treatment
Other interventions in this design: Doxorubicin (DOX, 25316‐40‐9, MedChemExpress, USA) 150 ng/mL. Compound effect isolated by the comparison: from approximately 85% in the DOX‐treated group to about 20%.
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: GW9508

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Culture (S16); Materials and Methods > SA‐β‐Gal Assay (S39); Results > GW9508 Enhanced the Viability of Senescent iTECs (S111, S114, S115); FIGURE 3 legend (S179, S187)

quantification of SA‐β‐gal positive cells: quantification of SA‐β‐gal positive cells; comparator: DOX‐treated group — Results > GW9508 Enhanced the Viability of Senescent iTECs (S115); FIGURE 3 legend (S179)

In Vivo Studies

In naturally aged female C57BL/6J mice, intraperitoneal GW9508 significantly increased thymus size and thymic index compared with the DMSO control group, particularly at 12.5 mg/kg and 25 mg/kg. In Sprague-Dawley neonatal pups with GMH, intranasal GW9508 at 2.5 mg/kg and 7.5 mg/kg significantly improved negative geotaxis 90-degree test outcomes compared with the GMH + vehicle group during the first 3 days post-GMH. [2,3]

Thymic changes in naturally aged mice

Animal study · 17‐month‐old naturally aged female C57BL/6J mice; n = 5 [2]

Naturally aged female C57BL/6J mice received GW9508 by intraperitoneal injection. Treatment significantly increased thymus size and thymic index compared with the DMSO control group, particularly at 12.5 mg/kg and 25 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
quantification of thymic indexReported result GW9508 treatment significantly increased thymus size and the thymus index, particularly in the 12.5 mg/kg and 25 mg/kg dosage groups, compared to the DMSO control group[2]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
every other day for a total of 15 doses
Vehicle
Dimethyl Sulfoxide, DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GW9508 12.5 mg/kg, 25 mg/kg, 50 mg/kgvehicle control group receiving solvent DMSOGW9508 treatment significantly increased thymus size and the thymus index, particularly in the 12.5 mg/kg and 25 mg/kg dosage groups, compared to the DMSO control group[2]
GW9508 12.5 mg/kg, 25 mg/kg, 50 mg/kg
Model: 17‐month‐old naturally aged female C57BL/6J mice; n = 5
Methods and source locations

Compound reported in the paper: GW9508

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Mice and Ethical Considerations (S2); Results > GW9508 Increased the Thymus Index in Aged Mice (S70, S71, S72, S74); FIGURE 1 legend (S157, S160)

quantification of thymic index: quantification of thymic index; comparator: vehicle control group receiving solvent DMSO — Results > GW9508 Increased the Thymus Index in Aged Mice (S74); FIGURE 1 legend (S157)

GW9508 12.5 mg/kg, 25 mg/kg, 50 mg/kg · Results > GW9508 Increased the Thymus Index in Aged Mice (S71, S72, S74)

Negative Geotaxis Outcomes in Neonatal Pups After GMH

Animal study · P7 Sprague-Dawley neonatal pups; GMH; n = 6 per group [3]

Sprague-Dawley neonatal pups with GMH received intranasal GW9508 at 2.5 mg/kg and 7.5 mg/kg. Treatment significantly improved outcomes in the negative geotaxis 90-degree test compared with the GMH + vehicle group during the first 3 days post-GMH.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
negative geotaxis 90-degree testReported result GW9508 treatment at a dosage of 2.5 mg/kg and 7.5 mg/kg demonstrated significant improvements in outcomes in the negative geotaxis 90-degree test when compared with the GMH + vehicle group in the first 3 days post-GMH.[3]

Conditions shared by the study groups

Route
intranasally (i.n.)
Treatment course
1 h, 25 h and 49 h after GMH
Vehicle
10% dimethyl sulfide
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GW9508 2.5 mg/kg, 7.5 mg/kgGMH + vehicleGW9508 treatment at a dosage of 2.5 mg/kg and 7.5 mg/kg demonstrated significant improvements in outcomes in the negative geotaxis 90-degree test when compared with the GMH + vehicle group in the first 3 days post-GMH.[3]
GW9508 2.5 mg/kg, 7.5 mg/kg
Model: P7 Sprague-Dawley neonatal pups; GMH; n = 6 per group
Methods and source locations

Compound reported in the paper: GW9508

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S2); Materials and methods > Germinal matrix hemorrhage (GMH) model (S6); Materials and methods > Experimental design > Experiment 2: The effects of GPR40 activation on short-term outcomes after GMH (S15, S16); Materials and methods > Drug administration > Intranasal drug administration (S40); Results > Intranasal administration of GW9508 improved short-term neurobehavioral outcomes at 3 days after GMH (S92)

negative geotaxis 90-degree test: negative geotaxis 90-degree test; comparator: GMH + vehicle — Results > Intranasal administration of GW9508 improved short-term neurobehavioral outcomes at 3 days after GMH (S92)

GW9508 2.5 mg/kg, 7.5 mg/kg · Materials and methods > Experimental design > Experiment 2: The effects of GPR40 activation on short-term outcomes after GMH (S16); Materials and methods > Drug administration > Intranasal drug administration (S40); Results > Intranasal administration of GW9508 improved short-term neurobehavioral outcomes at 3 days after GMH (S92)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 885101-89-3
Applications GPR40 Inhibitor
Formula C22H21NO3
Molecular Weight 347.4
SMILES
C1=CC=C(C=C1)OC2=CC=CC(=C2)CNC3=CC=C(C=C3)CCC(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 63 mg/mL (181.34 mM)
Water Insoluble
Ethanol 63 mg/mL (181.34 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
2% DMSO+40% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Mao XF, Wu HY, Tang XQ, et al. Activation of GPR40 produces mechanical antiallodynia via the spinal glial interleukin-10/β-endorphin pathway. J Neuroinflammation (2019). PMID: 30981281 DOI: 10.1186/s12974-019-1457-9 Source material
  2. [2] Li Q, Zhu P, Cui L, et al. GW9508-Induced Activation of GPR40 in Thymic Epithelial Cells: A Therapeutic Strategy to Delay Thymic Aging. Aging Cell (2026). PMID: 42444033 DOI: 10.1111/acel.70630 Source material
  3. [3] Xiao J, Cai T, Fang Y, et al. Activation of GPR40 attenuates neuroinflammation and improves neurological function via PAK4/CREB/KDM6B pathway in an experimental GMH rat model. J Neuroinflammation (2021). PMID: 34275493 DOI: 10.1186/s12974-021-02209-9 Source material

Added to your cart

View Cart Checkout
Loading...